
Sign up to save your podcasts
Or
Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Renal Denervation
FDA OKs Paradise Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998237
- Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/
- Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941
- March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014
II. Potential Deadly Decisions in the ED
Even One Night in the ED Raises Risk for Death
https://www.medscape.com/viewarticle/998080
- JAMA Internal Medicine Study
III. Tirzepatide Approval
FDA Approves Tirzepatide for Treating Obesity
https://www.medscape.com/viewarticle/998225
- SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X
- SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
IV. AHA Preview
Mandrola's Top Trials to Look for at AHA 2023
https://www.medscape.com/viewarticle/998123
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
4.9
826826 ratings
Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Renal Denervation
FDA OKs Paradise Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998237
- Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/
- Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941
- March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014
II. Potential Deadly Decisions in the ED
Even One Night in the ED Raises Risk for Death
https://www.medscape.com/viewarticle/998080
- JAMA Internal Medicine Study
III. Tirzepatide Approval
FDA Approves Tirzepatide for Treating Obesity
https://www.medscape.com/viewarticle/998225
- SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X
- SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
IV. AHA Preview
Mandrola's Top Trials to Look for at AHA 2023
https://www.medscape.com/viewarticle/998123
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
131 Listeners
13 Listeners
323 Listeners
160 Listeners
493 Listeners
18 Listeners
276 Listeners
3,318 Listeners
87 Listeners
134 Listeners
1,083 Listeners
60 Listeners
186 Listeners
513 Listeners
348 Listeners
59 Listeners
25 Listeners
8 Listeners
423 Listeners
366 Listeners